Celldex Therapeutics (CLDX) Stock Rises Today on High Volume

NEW YORK (TheStreet) -- Shares of Celldex Therapeutics  (CLDX) surged 13.83% to $21.32 in early afternoon trading Thursday on higher-than-average volume.

The stock soared Monday after the company announced positive results of its immunotherapy in treating a certain type of brain tumor.

The company announced its experimental, targeted immunotherapy called rindopepimut, combined with Roche's  (RHHBY)  Avastin, delayed tumor growth and extended survival in patients with a specific kind of recurring brain tumor. The interim results came from a mid-stage trial, and the data was presented during a medical meeting on Friday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Celldex organized the study for rindopepimut to be exploratory rather than for seeking regulatory approval, but the positive results led the company to say it is considering meeting with the FDA after the final data emerges in three to six months.

For more on Celldex's results, read TheStreet's Adam Feuerstein's in-depth coverage here.

More than 5.4 million shares had changed hands as of 12:02 p.m., compared to the daily average volume of 2,563,690.

CLDX Chart CLDX data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists